Computational and experimental insights into quinazoline derivatives: Targeting HOTAIR for therapeutic intervention

Ali M Alqahtani1, Taha Alqahtani1, Stalin Arulsamy2

  • 1Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.

Insights

New quinazoline derivatives show promise for breast cancer treatment by targeting HOTAIR (HOX transcript antisense intergenic RNA). Compound P14 exhibits strong binding and cytotoxicity, suggesting potential for novel therapeutic strategies.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Computational Biology

Background:

  • Breast cancer remains a leading cause of cancer mortality, necessitating innovative therapeutic approaches.
  • Existing treatments have limitations, driving research into targeted therapies.
  • Quinazoline derivatives are emerging as promising anticancer agents.

Purpose of the Study:

  • To investigate the potential of 5,6,7,8-tetrahydroquinazoline derivatives as targeted therapy for breast cancer.
  • To explore the molecular interactions between quinazoline derivatives and HOTAIR (HOX transcript antisense intergenic RNA).
  • To evaluate the anticancer activity and drug-like properties of these compounds.

Main Methods:

  • Computational studies including molecular docking and molecular dynamics simulations were employed.
  • Binding affinity between 25 quinazoline derivatives and HOTAIR was assessed.
  • In vitro cytotoxicity was evaluated using MTT assays.
  • ADMET analysis was performed to predict pharmacokinetic properties.

Main Results:

  • Compound P14 demonstrated the highest binding affinity to HOTAIR with a docking score of -9.4 kcal/mol.
  • Molecular dynamics simulations confirmed the stable interaction between HOTAIR and P14.
  • MTT assays revealed dose-dependent cytotoxicity, with P14 showing an IC50 of 57.73 µM.
  • ADMET analysis indicated potential bioavailability for P14, with noted toxicity concerns.

Conclusions:

  • Quinazoline derivatives, particularly P14, show significant potential as therapeutic agents against HOTAIR-mediated breast cancer.
  • P14's strong binding to HOTAIR and in vitro cytotoxicity support its further investigation.
  • Further preclinical studies are warranted to address toxicity and confirm efficacy.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
929
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
793